A recent study led by Emidio Pistilli, Ph.D., associate professor in the WVU School of Medicine Division of Exercise Physiology and the Department of Microbiology, Immunology, and Cell Biology, suggests that molecular alterations in the cell tissue of breast cancer patients may be the cause of fatigue in patients.
Dr. Pistilli worked with Elena Pugacheva, Ph.D., director of the Preclinical Tumor Models Core Facility at the WVU Cancer Institute, to obtain skeletal muscles from animal models that were implanted with human breast tumors. Their research found that muscle fatigue increased with the progression of tumor growth.
In the next stage of the study, Pistilli partnered with Hannah Hazard-Jenkins, M.D., associate chair of surgery for Cancer Services at the Cancer Institute, to obtain muscle biopsies of breast cancer patients at the time of their mastectomy surgery and isolate the genetic material in order to study the fatigue properties of the muscles.
“We used numerous computer algorithms to determine which genes were affected in the muscles,” Pistilli said. “Our data show that multiple pathways, which are sets of protein interactions in a cell that regulate muscle fatigue, were negatively affected. More importantly, the molecular changes in the muscles of breast cancer patients were highly similar to what we found in the animal muscles, supporting our observation of greater muscle fatigue with tumor growth.”
The next stage of their research will use the animal model they developed to test therapeutic interventions targeting pathways involved in muscle fatigue. Pistilli is applying for a grant from the National Institutes of Health to fully determine the mechanisms that contribute to muscle fatigue associated with breast cancer and identify mechanisms to alleviate that fatigue in patients.
The study titled “Dysregulation of metabolic-associated pathways in muscle of breast cancer patients: preclinical evaluation of interleukin-15 targeting fatigue” was published in the March 26 issue of the Journal of Cachexia, Sarcopenia and Muscle.
In addition to Drs. Pugacheva and Hazard-Jenkins, research collaborators include Mary Davis, Ph.D., professor emeritus in the Department of Physiology, Pharmacology, and Neuroscience; Joseph Bohlen, research assistant in the Division of Exercise Physiology; Sarah L. McLaughlin, biological technician at the WVU Cancer Institute Animal Models and Imaging Facility; Aniello M. Infante, lead bioinformatician at the WVU Genomics Core Facility; and Cortney Montgomery, B.S.N., R.N., research nurse in the WVU Clinical Trials Research Unit.
Bonnie’s Bus, a 45-foot, state-of-the-art mobile mammography vehicle, will visit Lewis and Glimer counties offering three-dimensional (3D) digital mammograms and breast care education to women.
When Kaylyn Faidley of Cumberland, Maryland, went for a routine ultrasound during her pregnancy, she found out that her daughter, Karlie, had right side hydronephrosis, a dilation or swelling of the right kidney. In most cases, this condition resolves on its own. In Karlie’s case, it caused frequent pain and urinary tract infections.
WVU Cancer Institute offering groundbreaking treatment for gastroenteropancreatic neuroendocrine tumors
The WVU Cancer Institute is participating in the implementation of a new drug therapy for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. These life-threatening tumors can spread to other organs, such as the liver.